Trevena Stock Forecast, Price & News

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena or view top-rated stocks.

How has Trevena's stock been impacted by Coronavirus (COVID-19)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRVN stock has decreased by 31.3% and is now trading at $0.48.
View which stocks have been most impacted by COVID-19.

Are investors shorting Trevena?

Trevena saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 5,600,000 shares, a decrease of 22.5% from the December 31st total of 7,230,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the short-interest ratio is presently 3.8 days. Approximately 3.6% of the shares of the stock are short sold.
View Trevena's Short Interest.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Trevena.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) issued its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company earned $0.18 million during the quarter, compared to analysts' expectations of $1.16 million. Trevena had a negative net margin of 7,771.74% and a negative trailing twelve-month return on equity of 53.47%. During the same quarter in the previous year, the firm earned ($0.04) EPS.
View Trevena's earnings history.

What price target have analysts set for TRVN?

2 Wall Street analysts have issued 1-year target prices for Trevena's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Trevena's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,150.0% from the stock's current price.
View analysts' price targets for Trevena or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:

• Carrie L. Bourdow, President, Chief Executive Officer & Director (LinkedIn Profile)
• Barry Shin, Chief Financial Officer & Senior Vice President
• Mark A. Demitrack, Chief Medical Officer & Senior Vice President
• Angela Bagley, Vice President-Technical Operations
• Michael J. Fossler, VP-Clinical Development & Quantitative Sciences

Who are some of Trevena's key competitors?

Some companies that are related to Trevena include Oramed Pharmaceuticals (ORMP), XBiotech (XBIT), Mersana Therapeutics (MRSN), Applied Molecular Transport (AMTI), Adagene (ADAG), AC Immune (ACIU), Nkarta (NKTX), Theratechnologies (THTX), Sernova (SEOVF), Immunic (IMUX), VistaGen Therapeutics (VTGN), Pyxis Oncology (PYXS), Viking Therapeutics (VKTX), Immuneering (IMRX) and Zomedica (ZOM).
View all of TRVN's competitors.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.48.

How much money does Trevena make?

Trevena has a market capitalization of $78.97 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29.37 million in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

Where are Trevena's headquarters?

Trevena is headquartered at 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].